Systemic HypertensionSystemic Hypertension2075-082X2542-2189Intermedservice Ltd3353110.26442/2075082X.2019.3.190252Research ArticleTarget levels of blood pressure in the elderly and very old patients with chronic kidney disease without frailtyOstroumovaOlga DD. Sci. (Med.), Prof.ostroumova.olga@mail.ruCherniaevaMarina SCand. Sci. (Med.)Pilya.ru@mail.ruPirogov Russian National Research Medical UniversityCentral State Medical Academy of Department of Presidential Affairs1509201916361216042020Copyright © 2019, Consilium Medicum2019Currently, people has been paying special attention to the problem of arterial hypertension (AH) in patients of the elderly and very old patients. The expected benefits from the treatment of AH compared to the potential harm in this age group of patients are increasingly being questioned, since they often have disturbed the mechanisms that maintain homeostasis and vital organ perfusion, especially pronounced in “frailty“ elderly and very old patients. Existing randomized clinical trials have shown that antihypertensive therapy in patients of elderly and very old significantly reduces cardiovascular morbidity, as well as cardiovascular mortality and all-cause mortality, however, the target blood pressure (BP) values are still debatable. A number of comorbidities also affect the determination of target levels of BP reduction. For example, AH is a major risk factor for its development and progression for chronic kidney disease (CKD). Therefore, it is important to understand the strategy of treating patients of elderly and very old with concomitant CKD. This article presents a review of the literature on target BP values in elderly and very old patients without frailty with diabetic and non-diabetic CKD. We reviewed data from large studies and meta-analyzes, assessing the relationship of more intensive compared with less intensive control of BP with a reduced risk of major cardiovascular events, mortality or changes in glomerular filtration rate. During the analysis of the literature, it was shown that the studies are extremely controversial: along with the benefits obtained in some of them from lowering BP of less than 130 mm Hg in terms of reducing mortality, cardiovascular risk and rates of progression of CKD, other studies have obtained results indicating not only the absence of these advantages, but also a clear advantage of higher target BP figures. Thus, there is a need for large, specially designed randomized clinical trials devoted to this issue.hypertensionblood pressuretarget blood pressure levelselderly and very old patientschronic kidney diseaseартериальная гипертонияартериальное давлениецелевые уровни артериального давленияпожилые и очень пожилые пациентыхроническая болезнь почек[2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; 39 (33): 3021-104. DOI: 10.1093/eurheartj/ehy339][Jafar T.H, Stark PC, Schmid C.H et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensinconverting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003; 139: 244-52.][Upadhyay A, Earley A, Haynes S.M, Uhlig K. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann Intern Med 2011; 154: 541-8.][Sim J.J, Shi J, Kovesdy C.P et al. Impact of achieved blood pressures on mortality risk and end-stage renal disease among a large, diverse hypertension population. J Am Coll Cardiol 2014; 64: 588-97.][Malhotra R, Nguyen H.A, Benavente O et al. Association Between More Intensive vs Less Intensive Blood Pressure Lowering and Risk of Mortality in Chronic Kidney Disease Stages 3 to 5: A Systematic Review and Meta-analysis. JAMA Intern Med 2017; 177 (10): 1498-505. DOI: 10.1001/jamainternmed.2017.4377][Cheung A.K, Rahman M, Reboussin D.M et al. Effects of Intensive BP Control in CKD. J Am Soc Nephrol 2017; 28 (9): 2812-23. DOI: 10.1681/ASN.2017020148][Wright J.T Jr, Bakris G, Greene T et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288 (19): 2421-31.][Toto R.D, Mitchell H.C, Smith R.D et al. “Strict” blood pressure control and progression of renal disease in hypertensive nephrosclerosis. Kidney Int 1995; 48 (3): 851-9.][Wright J.T Jr, Williamson J.D, Whelton P.K et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015; 373 (22): 2103-16.][Estacio R.O, Jeffers B.W, Gifford N, Schrier R.W. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000; 23 (Suppl. 2): B54-B64.][Schrier R.W, Estacio R.O, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002; 61 (3): 1086-97.][UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317 (7160): 703-13.][Heerspink H.J, Ninomiya T, Perkovic V et al. Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. Eur Heart J 2010; 31 (23): 2888-96.][Cushman W.C, Evans G.W, Byington R.P et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362 (17): 1575-85.][Lonn E.M, Bosch J, López-Jaramillo P et al; HOPE-3 Investigators. Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 2016; 374 (21): 2009-20.][Beckett N.S, Peters R, Fletcher A.E et al; Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358 (18): 1887-98.][Klahr S, Levey A.S, Beck G.J. et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med 1994; 330 (13): 877-84.][Mant J, McManus R.J, Roalfe A et al. Different systolic blood pressure targets for people with history of stroke or transient ischaemic attack: PAST-BP (Prevention After Stroke-Blood Pressure) randomised controlled trial. BMJ 2016; 352: i708.][Ruggenenti P, Perna A, Loriga G et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet 2005; 365 (9463): 939-46.][Schrier R, McFann K, Johnson A et al. Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study. J Am Soc Nephrol 2002; 13 (7): 1733-9.][SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research. JAMA 1991; 265 (24): 3255-64.][Benavente O.R, Coffey C.S, Conwit R et al; SPS3 Study Group. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet 2013; 382 (9891): 507-15.][Staessen J.A, Fagard R, Thijs L et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 997; 350 (9080): 757-64.][Tsai W.C, Wu H.Y Peng Y.S et al. Association of Intensive Blood Pressure Control and Kidney Disease Progression in Nondiabetic Patients With Chronic Kidney Disease: A Systematic Review and Meta-analysis. JAMA Intern Med 2017; 177 (6): 792-9. DOI: 10.1001/jamainternmed.2017.0197][Hayashi K, Saruta T, Goto Y et al. Impact of renal function on cardiovascular events in elderly hypertensive patients treated with efonidipine. Hypertens Res 2010; 33 (11): 1211-20.]